The 7 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 4.70, with a high estimate of 6.00 and a low estimate of 3.00. The median estimate represents a +54.61% increase from the last price of 3.04.
The current consensus among 10 polled investment analysts is to Hold stock in Nektar Therapeutics. This rating has held steady since October, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.45
Reporting Date Mar 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.